This is one of Roadmap's ready-made topic templates — a starting point for tracking something over time without writing a tracking brief from scratch.
Roadmap is an AI-assisted document editor: markdown with a live preview, a discussion panel where you can ask the AI about a specific section and apply its suggested edit straight to the text (you choose exactly what goes into each request's context), version history with restore, and export in multiple formats. Its "AI Update" button, on any document, searches the web for what has changed since you last checked and updates the document — with dates and sources — only when it finds something genuinely new.
To use this template: click "Open in Editor" above to copy it into your own documents, then press "AI Update" whenever you want to check for news. Browse the sidebar for more topics and categories.
Chronic Condition: Rheumatoid Arthritis
Brief
Tracking new guidelines and research on rheumatoid arthritis: updated clinical guidelines from relevant associations, new drugs and their approvals, results of major studies. Not needed: forum discussions without a cited source, supplement ads.
Description
The latest treatment guidelines have deliberately gotten simpler rather than more exhaustive, with growing attention to managing sustained remission long-term and an expanding set of options when a therapy stops working.
Updated EULAR Guidelines
EULAR released updated recommendations in early 2026, condensing them from 12 to 9 — fewer rules, sharper guidance. Methotrexate remains the cornerstone of first-line therapy, with glucocorticoids recommended only as short-term bridging therapy.
Escalation and Remission Management
When response is inadequate, biological DMARDs are recommended, with JAK inhibitors considered after careful risk assessment. For patients in sustained remission, the updated guidelines support gradually reducing medication under close supervision — but completely stopping treatment is not recommended, since RA relapses in most patients who do.
Treatment-Failure Options
When a therapy stops working, options include switching biologic classes (e.g., a TNF blocker to an IL-6 blocker or abatacept), adding a different medication, or trying a JAK inhibitor — with the guidelines emphasizing shared decision-making between patient and clinician.